文章：

套细胞淋巴瘤（MCL）的下一代疗法：CAR-T细胞治疗后复发/难治性治疗格局的演变

Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells

原文发布日期：3 July 2025

DOI: 10.3390/cancers17132239

类型: Article

开放获取: 是

英文摘要：

Mantle cell lymphoma (MCL) is a rare but heterogeneous subtype of non-Hodgkin lymphoma (NHL) with a prognosis ranging from very favorable in indolent cases to a poor prognosis for more aggressive variants [...]

摘要翻译： 

套细胞淋巴瘤（MCL）是一种罕见但具有异质性的非霍奇金淋巴瘤（NHL）亚型，其预后范围广泛，从惰性病例的非常良好到侵袭性变异型的较差预后。

原文链接：

Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells